Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2325-2328

  Mystakidou, Kyriaki ^a   Katsouda, Emmanuela ^a   Tsilika, Eleni ^a   Smyrniotis, Vassilios ^a   Vassiliou, Ioannis ^a   Tsiatas, Marinos ^a   Vlahos, Lambros ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chronic diarrhea; Long acting; Octreotide

Indexed keywords

LOPERAMIDE; OCTREOTIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER PATIENT; CHRONIC DIARRHEA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG FORMULATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE;

ADULT; AGED; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DIARRHEA; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LOPERAMIDE; MALE; MIDDLE AGED; NEOPLASMS; OCTREOTIDE; QUALITY OF LIFE;

EID: 33745538721     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Cartoni C, Dragoni F, Micozzi A et al: Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol 19: 756-761, 2001.
2. Tuchman L and Engelking C: Cancer-related diarrhea. In: Oncology Nursing Secrets. 2nd ed. Gates RA and Fink RM (eds.). Philadelphia, Pa: Hanley and Belfus, pp. 310-322, 2001.
3. Bruckstein AH: Acute diarrhea. Am Fam Physician 38: 217-228, 1998.
4. Abigerges D, Armand JP, Chabot GG et al: Irinotecan (CPT-11) high dose escalation using intensive high dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446-449, 1994.
5. Walder S, Benson AB, Engelking C et al: Recommended guidelines for the treatment of chemotherapy induced diarrhea. J Clin Oncol 16: 3169-3178, 1998.
6. Sykes NP: Constipation and diarrhea. In: Oxford Textbook of Palliative Medicine. 2nd ed. Doyle D, Hanks GW and MacDonald N (eds.). New York, NY: Oxford University Press, pp. 513-526, 1998.
7. Kornblau S, Benson AB, Catalano R et al: Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 19: 118-129, 2000.
8. Mercadante S: Diarrhea in terminally ill patients: pathophysiology and treatment. J Pain Symptom Manage 10: 298-309, 1995.
9. Cello JP, Grendell JH, Basuk P et al: Effect of octreotide on refractory AIDS-associated diarrhea. A prospective, multicenter clinical trial. Ann Intern Med 115: 705-710, 1991.
10. Walder S, Haynes H, Wiernik PH et al: Phase I trial of somtostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 13: 222-226, 1995.
11. Ippoliti C: Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm 55: 1573-1580, 1998.
12. Ippoliti C, Champlin R, Bugazia N et al: Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 75: 3350-3354, 1997.
13. Morton AJ and Durrant ST: Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation. Clin Transplant 9: 205-208, 1995.
14. Rubin J, Ajani J, Schirmer W et al: Octreotide acetate long-acting formulation vs. open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17: 600-606, 1999.
15. Rosenoff SH: Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy. Eur J Cancer Care 13: 380-383, 2004.
16. Rosenoff S: Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer 12: 561-570, 2004.
17. Barbounis V, Koumakis G, Vassilomanolakis M et al: Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9: 258-260, 2001.